Alterity Therapeutics (NASDAQ:ATHE) Price Target Raised to $12.00

Alterity Therapeutics (NASDAQ:ATHE) had its target price hoisted by Maxim Group from $8.00 to $12.00 in a research note released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Alterity Therapeutics Trading Up 57.0 %

ATHE opened at $4.57 on Thursday. The firm’s 50 day moving average is $2.71 and its 200-day moving average is $1.81. Alterity Therapeutics has a 52-week low of $1.00 and a 52-week high of $5.87.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC lifted its holdings in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,883 shares of the company’s stock after acquiring an additional 8,100 shares during the quarter. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 as of its most recent filing with the SEC. Institutional investors own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.